Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Lantheus' oncology portfolio includes Pylarify (piflufolastat F 18) and a growing pipeline addressing various solid tumours.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

The European Medicines Agency (EMA) has joined the hordes of users abandoning Elon Musk's X.com (formerly Twitter) and will ...

The Food & Drug Administration (FDA), has quietly taken down their guidance detailing diversity action plans for clinical ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...